Navigation Links
XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
Date:6/30/2008

nt.getElementById('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >XTLB; TASE: XTL).

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for our clinical compound for neuropathic pain, Bicifadine, the likelihood of successful results from a clinical trial with Bicifadine, operating strategies and similar matters, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete the Phase 2b clinical trial with Bicifadine and obtain positive trial results from the Phase 2b clinical trial, all of which will directly impact our ability to continue to fund our operations; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission, including our annual report on Form 20-F filed with the Securities and Exchange Commission on March 27, 2008. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.xtlbio.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
2. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
3. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
5. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
6. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
7. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
8. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
9. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Market Research Report on Global and Chinese ... and in-depth market survey on Global and ... firstly reviews the basic information of X-Ray Crystallography ... The report then explores global and China,s top ... specification, capacity, Production value, and market share etc. ...
(Date:8/29/2014)... ANGELES , Aug. 29, 2014  Chuma ... both financing alternatives and turnkey support services for ... announce that FINRA processed and approved the Company,s ... 29, 2014, CannaMed Corporation will be known as ... change was accomplished through a merger with the ...
(Date:8/29/2014)... HILL, N.C. , Aug. 29, 2014 ... Leaders (KOLs) can be the difference between a product,s ... to effectively map and stratify KOL targets – and ... build the type of strong relationships upon which successful ... research, savvy pharma companies have identified internal inconsistencies in ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Implementing a Strategic Thought Leader Management & Engagement System 2
... Biosciences announced,today, the initiation of a Phase 2 ... management of acute infectious,mononucleosis. Currently, there are no ... or any other disease caused by,the Epstein-Barr virus ... of anti-viral activity,including inhibition of viral replication of ...
... Dec. 6 Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) ... ), has begun a Phase 1 clinical trial of ... R343,for the treatment of allergic asthma. R343 is the ... terms of the companies, 2005 collaboration agreement, Rigel,will receive ...
Cached Medicine Technology:Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 3
(Date:8/30/2014)... Pittsburgh, PA (PRWEB) August 30, 2014 "I ... beach because of her crutches," said an inventor from Wetumpka, ... the sights and sounds of the shore, I came up ... beach sand." , She created a prototype for the patent-pending ... The accessory enables the individual to use crutches, walkers, or ...
(Date:8/30/2014)... 30, 2014 In today’s world, a good ... get. Snoring and sleep apnea (a medical problem where the ... their bed partners of the rest they need to face ... population snores and 20 million people in the United States ... diagnosed and treated; and of those treated, many cannot tolerate ...
(Date:8/30/2014)... Seattle, WA (PRWEB) August 30, 2014 One ... of this era is the gluten-free diet. Originally meant for ... has become a catchall for people who are looking to ... gluten. However, not only is this kind of information erroneous, ... of health problems because of a drastic change in ...
(Date:8/30/2014)... Colorado (PRWEB) August 30, 2014 The new ... Cure program was created by Karen Brimeyer, who wanted to ... world. , This guide is now easy to find ... instant download. In this guide, the author of the new ... cure. , Daily Gossip writes in its review that ...
(Date:8/30/2014)... 2014 August 28th, 2014: With ... our society and the toll that takes on the ... that continuing education for physical therapists addresses this problem. ... therapists help others, Hands-On Seminars is offering discounts on ... Three learning styles are available to fit the individual ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2
... heads to India to share his proven and simple strategies in ... Businesses. Long concerned and fascinated with India's obvious human and economical ... distressed businesses in slow economies. , ... Los Angeles, ...
... 15, 2008 A long-time microbial inhabitant of the human ... new study among more than 7,000 subjects led by NYU ... a bacterium that has co-existed with humans for at least ... Yet, kids between the ages of 3 and 13 are ...
... than 1500 nutritional supplements ... ... Creating Wellness Alliance,(CWA), experts in designing custom wellness programs for ... supplement,Vitalize. The announcement was made by biochemist, Lyle MacWilliam, author,of ...
... July 14 In response to the many,people who have ... Family,Trust" was set up today to help with Tony Snow,s ... as the Trustee with Tony Snow,s,three children, Kendall, Robbie and ... Snow Family Trust" by either sending a check,made payable to ...
... of American,Physicians, Inc. (CAP) today announced that its ... 10,000 member level truly represents a milestone for,our ... who founded,CAP more than 30 years ago were ... find a way to manage the escalating costs,of ...
... with upbeat outlook, but same did not hold true for women ... had a lower risk of dying from heart disease turned out ... their conventional risk factors showed. , The death rate for men ... of those who listed themselves as being at average risk, said ...
Cached Medicine News:Health News:The Five Biggest Marketing Mistakes Made By Medical Offices and Small Businesses 2Health News:Stomach bug appears to protect kids from asthma, says NYU study 2Health News:Stomach bug appears to protect kids from asthma, says NYU study 3Health News:Vitalize(TM) Receives Top Multivitamin Rating 2Health News:Cooperative of American Physicians Membership Tops 10,000 2Health News:Optimism About Heart Risk Pays Off 2
... Ergonomic Design for Unparalleled Comfort Pick ... Notice the balance. Notice the trigger and ejector ... Thats because our pipettors are ergonomically designed to ... hours of pipetting. Productivity In The Palm ...
... Ergonomic Design for Unparalleled Comfort ... it. Notice the balance. Notice the trigger and ... left-handed. Thats because our pipettors are ergonomically designed ... long hours of pipetting. Productivity In The ...
... The Finnpipette BioControl multichannel ... features as the single ... handle fits all seven ... channel tip cone modules. ...
... , The new Finnpipette Novus is so user-friendly that ... few minutes. With the intuitive instantly familiar menu and ... functions you need quickly and easily. The large, clear ... names of all functions. The easily accessible two ...
Medicine Products: